Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung15: Dato-DXd ± osimertinib vs platinum doublet after progression on osimertinib in EGFR-mutated NSCLC
ChiCTR2500095876Phase 3Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in EGFR-mutated non-small cell lung cancer (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Progression-free survival (Dato-DXd vs chemotherapy) and Progression-free survival (Dato-DXd + osimertinib vs chemotherapy). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2500095876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095876.